The NewCo model biopharma strategy has rapidly become one of the most consequential dealmaking trends in the life sciences industry. Rather than shelving deprioritised pipeline assets or selling them outright through traditional licensing agreements, major...
The first Phase 2 clinical evidence that a tau Alzheimer's drug can simultaneously reduce brain tangles and slow cognitive decline was presented at the Alzheimer's Association International Conference (AAIC) 2026 in London on 14 July. Biogen's diranersen, an antisense...
Pharmaceutical manufacturing is entering a new scientific era. For decades, the industry has relied on validated processes, fixed control strategies, laboratory testing and carefully documented batch records to prove that medicines are made consistently and safely....
The Medicare GLP-1 Bridge launched on 1 July 2026, opening a new pathway for eligible Medicare Part D beneficiaries to access weight management medications at a fixed monthly copay of $50. For clinicians navigating GLP-1 Bridge eligibility criteria, the prior...
When I wrote previously for this publication about the gap between GLP-1 prescribing rates and the clinical conversation around lean muscle preservation, the argument centred on a simple premise: weight loss is not fat loss, and the clinical infrastructure around...
In more than two decades of working with global CROs, pharmaceutical companies, and biotech organizations, I have watched pharmacovigilance teams absorb wave after wave of increasing complexity. More products on the market. More data sources to monitor. More...
By early Q4 2025, global pharma M&A had already crossed $70B in announced value, driven heavily by a handful of mega-deals, more than 2024, and tracking toward the highest levels since the post-2015 boom. Unlike 2023–24, this wave isn’t driven by small tuck-ins....
As the pharmaceutical industry undergoes rapid transformation, a new paradigm is taking shape. Known as Pharma 5.0, it represents more than an upgrade in technology, it is a fundamental shift toward human-centric innovation, sustainable manufacturing, and intelligent...
The National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending a novel, next-generation chimeric antigen receptor T-cell (CAR-T) therapy for use in the National Health Service (NHS). This landmark decision is set to...
Decision Frameworks in Pharma: From RAVE and DICE to Lilly’s Truth-Seeking Machine What Works, What Kills What, and Why It Matters In pharmaceutical R&D, where billions ride on the flip of a biological coin, decision frameworks aren’t just nice-to-haves - they’re...
Eight years on from the first version of this article, “follow the science” is still the industry’s favourite comfort blanket. It sounds noble, unassailable, the kind of thing you put on a lab-wall poster next to a photo of Rosalind Franklin. (Following the X...
Durvalumab approved in the US as first & only perioperative immunotherapy for patients with early gastric & gastroesophageal cancers! The FDA approved Durvalumab (Imfinzi) in combination with Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT)...
The biotech M&A boom shows no signs of slowing. Novartis has struck a definitive agreement to acquire Avidity Biosciences for US$12 billion in cash, marking one of the most consequential acquisitions in the RNA therapy space in recent years. The deal significantly...
AstraZeneca and Sun Pharma Join Forces to Expand Access to Hyperkalaemia Treatment in India In a major development for renal and cardiac care in India, AstraZeneca Pharma India and Sun Pharmaceutical Industries have announced a strategic co-marketing partnership to...
Johnson & Johnson has agreed to acquire Halda Therapeutics for $3.05 billion in cash, a transaction announced on 17 November 2025 and expected to close in the coming months, subject to customary regulatory approvals. Halda’s Novel RIPTAC Modality Halda...
The Chinese biotechnology sector continues to accelerate, signing high-value deals and expanding its global footprint even as the United States prepares new restrictions on collaborations and funding. Despite growing geopolitical tensions, China’s biopharma industry...
Why Sarcopenia Matters Sarcopenia, the age-related decline in skeletal muscle mass and strength, has become a growing concern in ageing populations. The condition contributes significantly to frailty, falls, fractures, disability and even mortality, placing an...
It is unusual for trade policy in the United States to have such a direct impact on the UK life sciences sector, but President Donald Trump’s proposed 100 per cent tariff on branded and patented pharmaceuticals could do just that. If enacted, the measure would impose...